9/16/2022 7:18:49 AM
Intellia Therapeutics, Regeneron Pharma Announce Positive Interim Results From Phase 1 Clinical Trial Of NTLA-200
9/15/2022 7:05:35 AM
Alnylam And Regeneron Report Promising Data From Phase 1 Study Of ALN-HSD In NASH Patients And Healthy Volunteers
9/12/2022 4:42:36 AM
Regeneron Pharma Presents Positive Neoadjuvant Libtayo Monotherapy Data At ESMO And Publishes In NEJM
9/12/2022 2:34:41 AM
REGN: Fianlimab Combination Shows Greater Than 60% Response Rates In Two Cohorts Of Patients With Advanced Melanoma
9/8/2022 9:04:21 AM
Regeneron :Aflibercept 8 Mg Meets Primary Endpoints In Two Global Pivotal Trials For DME And WAMD
8/3/2022 6:40:58 AM
Regeneron Pharmaceuticals (REGN) Has Raised Its FY22 Revenue Estimate To $3.100 - $3.240 Bln From $2.900 - $3.100 Bln
8/3/2022 6:31:52 AM
Regeneron Q2 GAAP EPS $7.47; Non-GAAP EPS $9.77
8/3/2022 6:28:44 AM
Regeneron Reports Encouraging Initial Data From Phase 1/2 Trial Of REGN5678 With Libtayo In Advanced MCRPC
7/14/2022 1:00:54 AM
Regeneron Pharma, Sanofi: Phase 3 Trial Of Dupixent In People With Eosinophilic Esophagitis Meets Primary Endpoint